retatrutide clinical trial phase retatrutide New 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats retatrutide clinical trials status 2025

PF-08653944 skin shot once a month uses more than one drug in one dose

Its onset is driven by obesity, sedentary behavior, and genetic predisposition, leading to insulin resistance, progressive beta-cell dysfunction, and complications such as cardiovascular disease and nonalcoholic fatty liver disease (NAFLD)

Every other day dosing is not a standard recommended protocol

Thornton K, and Gorenstein DG

XERF may be a beneficial option for clients experiencing skin laxity following weight loss, including changes associated with GLP-1 medications

We only recommend freezing if you are aliquoting the entire vial into single-use portions for a long-term study